{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:36:15Z","timestamp":1768484175358,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["204725-3"],"award-info":[{"award-number":["204725-3"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005029","name":"Helse Vest Regionalt Helsef\u00f8retak","doi-asserted-by":"publisher","award":["911709"],"award-info":[{"award-number":["911709"]}],"id":[{"id":"10.13039\/501100005029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40360-016-0061-1","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T15:27:49Z","timestamp":1461079669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)"],"prefix":"10.1186","volume":"17","author":[{"given":"Nikolaj","family":"Kun\u00f8e","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arild","family":"Opheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Klemmetsby","family":"Solli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanna","family":"Gaulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamni","family":"Sharma-Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zill-e-Huma","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,28]]},"reference":[{"key":"61_CR1","unstructured":"Number and age-adjusted rates of drug-poisoning deaths involving opioid analgesics and heroin: United States, 2000\u20132014. http:\/\/www.cdc.gov\/nchs\/data\/health_policy\/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf . Accessed 22 Dec 2015."},{"key":"61_CR2","first-page":"10","volume":"61","author":"Center for Disease Control","year":"2012","unstructured":"Center for Disease Control. CDC grand rounds: prescription drug overdoses\u2013a U.S. epidemic. Morb Mortal Wkly Rep. 2012;61:10\u20133.","journal-title":"Morb Mortal Wkly Rep"},{"key":"61_CR3","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2013tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063\u20136.","journal-title":"N Engl J Med"},{"key":"61_CR4","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","volume":"284","author":"AT McLellan","year":"2000","unstructured":"McLellan AT, Lewis DC, O\u2019Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689\u201395.","journal-title":"JAMA"},{"key":"61_CR5","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva; 2009."},{"key":"61_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","volume":"193","author":"VP Dole","year":"1965","unstructured":"Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646.","journal-title":"JAMA"},{"key":"61_CR7","volume":"2","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2, CD002207.","journal-title":"Cochrane Database Syst Rev"},{"key":"61_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1471-244X-13-262","volume":"13","author":"A Bukten","year":"2013","unstructured":"Bukten A, R\u00f8islien J, Skurtveit S, Waal H, Gossop M, Clausen T. A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study. BMC Psychiatry. 2013;13:262.","journal-title":"BMC Psychiatry"},{"key":"61_CR9","doi-asserted-by":"crossref","unstructured":"Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H. Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study. BMJ Open. 2011;1, e000130.","DOI":"10.1136\/bmjopen-2011-000130"},{"key":"61_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.forsciint.2012.11.010","volume":"224","author":"J-P Bernard","year":"2013","unstructured":"Bernard J-P, Havnes I, Sl\u00f8rdal L, Waal H, M\u00f8rland J, Khiabani HZ. Methadone-related deaths in Norway. Forensic Sci Int. 2013;224:111\u20136.","journal-title":"Forensic Sci Int"},{"key":"61_CR11","unstructured":"SAMSHA. Federal Guidelines for Opioid Treatment Programs. Rockville, MD; 2015"},{"key":"61_CR12","doi-asserted-by":"crossref","unstructured":"Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD. Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105:709\u201318.","DOI":"10.1111\/j.1360-0443.2009.02843.x"},{"key":"61_CR13","unstructured":"UNODC. World Drug Report. New York; 2014"},{"key":"61_CR14","first-page":"672","volume":"21","author":"CN Chiang","year":"1985","unstructured":"Chiang CN, Kishimoto A, Barnett G, Hollister LE. Implantable narcotic antagonists: a possible new treatment for narcotic addiction. Psychopharmacol Bull. 1985;21:672.","journal-title":"Psychopharmacol Bull"},{"key":"61_CR15","unstructured":"Alim TN, Tai B, Chiang CN, Green T, Rosse RB, Lindquist T, Deutsch SI. Tolerability study of a depot form of naltrexone substance abusers. NIDA Res Monogr. 1995;153:253."},{"key":"61_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","volume":"28","author":"HR Kranzler","year":"2004","unstructured":"Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"61_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","volume":"189","author":"MA Sullivan","year":"2006","unstructured":"Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacol. 2006;189:37\u201346.","journal-title":"Psychopharmacol"},{"key":"61_CR18","doi-asserted-by":"crossref","unstructured":"Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O\u2019Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210\u20138.","DOI":"10.1001\/archpsyc.63.2.210"},{"key":"61_CR19","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506\u201313.","journal-title":"Lancet"},{"key":"61_CR20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","volume":"66","author":"GK Hulse","year":"2009","unstructured":"Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66:1108\u201315.","journal-title":"Arch Gen Psychiatry"},{"key":"61_CR21","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","volume":"69","author":"E Krupitsky","year":"2012","unstructured":"Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69:973\u201381.","journal-title":"Arch Gen Psychiatry"},{"key":"61_CR22","doi-asserted-by":"crossref","unstructured":"Kun\u00f8e N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen \u00d8, Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2009;194:541\u20136.","DOI":"10.1192\/bjp.bp.108.055319"},{"key":"61_CR23","doi-asserted-by":"crossref","unstructured":"Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110:1008\u201314.","DOI":"10.1111\/add.12894"},{"key":"61_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","volume":"23","author":"Y-I Hser","year":"2015","unstructured":"Hser Y-I, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23:76\u201389.","journal-title":"Harv Rev Psychiatry"},{"key":"61_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/add.12208","volume":"108","author":"E Krupitsky","year":"2013","unstructured":"Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108:1628\u201337.","journal-title":"Addiction"},{"key":"61_CR26","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1360-0443.2012.03910.x","volume":"107","author":"E Kelty","year":"2012","unstructured":"Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. Addiction. 2012;107:1817\u201324.","journal-title":"Addiction"},{"key":"61_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/0269881110364266","volume":"25","author":"HTT Ngo","year":"2011","unstructured":"Ngo HTT, Tait RJ, Hulse GK. Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance. J Psychopharmacol. 2011;25:774\u201382.","journal-title":"J Psychopharmacol"},{"key":"61_CR28","first-page":"CD001333","volume":"4","author":"S Minozzi","year":"2011","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;4:CD001333.","journal-title":"Cochrane Database Syst Rev"},{"key":"61_CR29","first-page":"121","volume":"22","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Kranzler HR, Kusmierek J. A placebo-controlled, clinical trial of naltrexone depot in treatment of alcohol dependence: results at 9 and 12\u00a0months. J Addict Dis. 2003;22:121.","journal-title":"J Addict Dis"},{"key":"61_CR30","doi-asserted-by":"crossref","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617\u201325.","DOI":"10.1001\/jama.293.13.1617"},{"key":"61_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/00952997809007017","volume":"5","author":"S Sideroff","year":"1978","unstructured":"Sideroff S, Charuvastra V, Jarvik M. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse. 1978;5:415\u201323.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"61_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/science.278.5335.52","volume":"278","author":"GF Koob","year":"1997","unstructured":"Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52.","journal-title":"Science"},{"key":"61_CR33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5694\/j.1326-5377.2007.tb01126.x","volume":"187","author":"AE Gibson","year":"2007","unstructured":"Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants\u2013in reply. Med J Aust. 2007;187:56\u20137.","journal-title":"Med J Aust"},{"key":"61_CR34","unstructured":"European Medicines Agency. ICH Topic E 9\u2013statistical principles for clinical trials\u2013note for guidance on statistical principles for clinical trials. London; 1996."},{"key":"61_CR35","doi-asserted-by":"crossref","unstructured":"Keegan J, Lavenduski C, Schooff K. Comments and findings from a naltrexone double blind study. NIDA Res Monogr. 1976;74\u201376.","DOI":"10.1037\/e497452006-014"},{"key":"61_CR36","doi-asserted-by":"crossref","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 2:22\u201357.","DOI":"10.1037\/t18597-000"},{"key":"61_CR37","unstructured":"CDAG resources for authors http:\/\/cda.cochrane.org\/cdag-resources-authors . Accessed 7 Jan 2016."},{"key":"61_CR38","doi-asserted-by":"crossref","unstructured":"McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL, O\u2019Brien CP. New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis. 1985;173:412.","DOI":"10.1097\/00005053-198507000-00005"},{"key":"61_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000259089","volume":"1","author":"A Kokkevi","year":"1995","unstructured":"Kokkevi A, Hargers C. EUROPASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. 1995;1:208\u201310.","journal-title":"Eur Addict Res"},{"key":"61_CR40","first-page":"41","volume-title":"Timeline follow-back: a technique for assessing self-reported alcohol consumption","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB, Litten RZ, Allen JP. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Totowa, NJ: Humana Press; 1992. p. 41\u201372."},{"key":"61_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bs.3830190102","volume":"19","author":"LR Derogatis","year":"1974","unstructured":"Derogatis LR et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19:1\u201315.","journal-title":"Behav Sci"},{"key":"61_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1207\/s15327752jpa7002_11","volume":"70","author":"W Pavot","year":"1998","unstructured":"Pavot W, Diener E, Suh E. The Temporal Satisfaction With Life Scale. J Pers Assess. 1998;70:340\u201354.","journal-title":"J Pers Assess"},{"key":"61_CR43","doi-asserted-by":"crossref","unstructured":"Kun\u00f8e N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, Kristensen \u00d8, Waal H. Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction. 2010;105:1633\u20139.","DOI":"10.1111\/j.1360-0443.2010.03031.x"},{"key":"61_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1037\/0893-164X.10.2.81","volume":"10","author":"WR Miller","year":"1996","unstructured":"Miller WR, Tonigan JS. Assessing drinkers\u2019 motivation for change: the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychol Addict Beh. 1996;10:81\u20139.","journal-title":"Psychol Addict Beh"},{"key":"61_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","volume":"30","author":"R Melzack","year":"1987","unstructured":"Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191\u20137.","journal-title":"Pain"},{"key":"61_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1086\/658881","volume":"40","author":"T Hovde Lyngstad","year":"2011","unstructured":"Hovde Lyngstad T, Skardhamar T. Nordic register data and their untapped potential for criminological knowledge. Crime and Justice. 2011;40:613\u201345.","journal-title":"Crime and Justice"},{"key":"61_CR47","first-page":"CD006140","volume":"2","author":"P Lobmaier","year":"2008","unstructured":"Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;2:CD006140.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-016-0061-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-016-0061-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-016-0061-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-016-0061-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T03:33:21Z","timestamp":1655523201000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-016-0061-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,28]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1186\/s40360-016-0061-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,28]]},"article-number":"18"}}